Hypertension and Related Cardiovascular Disease Burden in China

Annals of Global Health

Volumn 82, Issue 2, 2016, Pages 227-233

  Bundy, Joshua D ^a   He, Jiang ^a  

^a TULANE UNIVERSITY   (United States)

Author keywords

cardiovascular disease; China; control; hypertension; mortality; prevalence; treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; AWARENESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHINA; CHINESE; DISEASE CONTROL; HUMAN; HYPERTENSION; MORBIDITY; PREVALENCE; REVIEW; SYSTEMATIC REVIEW (TOPIC); ATTITUDE TO HEALTH; BLOOD PRESSURE; EPIDEMIOLOGY; ETHNOLOGY; FEMALE; MALE; PHYSIOLOGY;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHINA; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPERTENSION; MALE; PREVALENCE;

EID: 84991474936     PISSN: None     EISSN: 22149996     Source Type: Journal    
DOI: 10.1016/j.aogh.2016.02.002     Document Type: Review

References (37)

1. 1 Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K., He, J., Global burden of hypertension: analysis of worldwide data. Lancet 365 (2005), 217–223.
2. 2 GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age – sex specific all-cause and cause-specific mortality for 240 causes of death, 1990 – 2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385 (2014), 118–171.
3. 3 He, J., Gu, D., Wu, X., et al. Major causes of death among men and women in China. N Engl J Med 353 (2005), 1124–1134.
4. 4 He, J., Gu, D., Chen, J., et al. Premature deaths attributable to blood pressure in China: a prospective cohort study. Lancet 374 (2009), 1765–1772.
5. 5 Yang, G., Wang, Y., Zeng, Y., et al. Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 381 (2013), 1987–2015.
6. 6 Wu, X., Duan, X., Gu, D., Hao, J., Tao, S., Fan, D., Prevalence of hypertension and its trends in Chinese populations. Int J Cardiol 52 (1995), 39–44.
7. 7 Wu, Y., Lu, C., Gao, R., Yu, J., Lie, G., Nation-wide hypertension screening in China during 1979–1980. Chin Med J 95 (1982), 101–108.
8. 8 Gu, D., Reynolds, K., Wu, X., et al. Prevalence, awareness, treatment, and control of hypertension in China. Hypertension 40 (2002), 920–927.
9. 9 Wu, Y., Huxley, R., Li, L., et al. Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002. Circulation 118 (2008), 2679–2686.
10. 10 Gao, Y., Chen, G., Tian, H., et al. Prevalence of hypertension in China: a cross-sectional study. PLoS One, 8, 2013, e65938.
11. 11 Wang, J., Zhang, L., Wang, F., Liu, L., Wang, H., Prevalence, awareness, treatment, and control of hypertension in China: Results from a National Survey. Am J Hypertens 27 (2014), 1–7.
12. 12 Li, Y.C., Wang, L.M., Jiang, Y., Li, X.Y., Zhang, M., Hu, N., Prevalence of hypertension among Chinese adults in 2010. Chin J Prev Med (Chinese) 46 (2012), 409–413.
13. 13 Xu, Y., Bi, Y., Li, M., et al. Prevalence, awareness, treatment, and control of hypertension in China. Circulation, 127, 2013, A005.
14. 14 Li, D., Lv, J., Liu, F., et al. Hypertension burden and control in mainland China: analysis of nationwide data 2003–2012. Int J Cardiol 184 (2015), 637–644.
15. 15 Hou, X., Urban–rural disparity of and untreated hypertension in China. Asia Pac J Public Health 20 (2008), 159–169.
16. 16 Reynolds, K., Gu, D., Muntner, P., et al. Geographic variations in the prevalence, awareness, treatment and control of hypertension in China. J Hypertens 21 (2003), 1273–1281.
17. 17 Zhao, L., Stamler, J., Yan, L.L., et al. Blood pressure differences between northern and southern Chinese: role of dietary factors the international study on macronutrients and blood pressure. Hypertension 43 (2004), 1332–1337.
18. 18 Li, W., Gu, H., Teo, K.K., et al. Hypertension prevalence, awareness, treatment, and control in 115 rural and urban communities involving 47,000 people from China. J Hypertens 34 (2016), 39–46.
19. 19 Guo, J., Zhu, Y.C., Chen, Y.P., Hu, Y., Tang, X.W., Zhang, B., The dynamics of hypertension prevalence, awareness, treatment, control and associated factors in Chinese adults: results from CHNS 1991-2011. J Hypertens 33 (2015), 1688–1696.
20. 20 Fang, L., Song, J., Ma, Z., Zhang, L., Jing, C., Chen, D., Prevalence and characteristics of hypertension in mainland Chinese adults over decades: a systematic review. J Hum Hypertens 28 (2014), 649–656.
21. 21 Wu, Z., Yao, C., Zhao, D., Wu, G., Sino-MONICA Project: a collaborative study on trends and determinants in cardiovascular diseases in China, part I: morbidity and mortality monitoring. Circulation 103 (2001), 462–468.
22. 22 Wu, Y., Liu, X., Li, X., et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. Circulation 114 (2006), 2217–2225.
23. 23 Liu, M., Wu, B., Wang, W.-Z., Lee, L.-M., Zhang, S.-H., Kong, L.-Z., Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurol 6 (2007), 456–464.
24. 24 Zhao, D., Liu, J., Wang, W., et al. Epidemiological transition of stroke in China: twenty-one–year observational study from the Sino-MONICA-Beijing Project. Stroke 39 (2008), 1668–1674.
25. 25 Gu, D., Kelly, T.N., Wu, X., et al. Blood pressure and risk of cardiovascular disease in Chinese men and women. Am J Hypertens 21 (2008), 265–272.
26. 26 Shen, W., Mingzhou, L., Gong, L., Beneficial effects of captopril on prognosis in patients with acute myocardial infarction. Chin Med J 109 (1996), 588–591.
27. 27 Gong, L., Zhang, W., Zhu, Y., et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 14 (1996), 1237–1245.
28. 28 Liu, L., Wang, J.G., Gong, L., Liu, G., Staessen, J.A., Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 16 (1998), 1823–1829.
29. 29 Wang, J.G., Staessen, J., Gong, L., Liu, L., Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 160 (2000), 211–220.
30. 30 Liu, L., Zhang, Y., Liu, G., Li, W., Zhang, X., Zanchetti, A., The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 23 (2005), 2157–2172.
31. 31 Turnbull, F., Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 (2003), 1527–1535.
32. 32 Wei, Y., Jin, Z., Shen, G., et al. Effects of intensive antihypertensive treatment on Chinese hypertensive patients older than 70 years. J Clin Hypertens 15 (2013), 420–427.
33. 33 Huo, Y., Li, J., Qin, X., et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China. JAMA, 313, 2015, 1325.
34. 34 Neal, B., MacMahon, S., Chapman, N., et al. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356 (2000), 1955–1964.
35. 35 Wang, J.G., Chinese Hypertension guidelines. Pulse 3 (2015), 14–20.
36. 36 SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 (2015), 2103–2116.
37. 37 Gu, D., He, J., Coxson, P.G., et al. The cost-effectiveness of low-cost essential antihypertensive medicines for hypertension control in China: a modelling study. PLoS Med, 12, 2015, e1001860.